INTRODUCTION
Adenovirus (AdV) vector-based vaccines have been shown to elicit balanced humoral and cell-mediated immune (CMI) responses 1, 2 by activating innate immunity through both Toll-like receptor (TLR)-dependent as well as TLR-independent pathways. 3, 4 Due to the high prevalence of AdV in humans, the development of AdV-specific neutralizing antibodies, known as "pre-existing vector immunity," [5] [6] [7] is one of the potential concerns for several human AdV (HAdV) vector-based vaccine delivery systems. To address this concern, a number of less prevalent HAdVs or nonhuman AdVs have been developed as vaccine delivery vectors. 8, 9 These nonhuman AdV vectors are based on bovine AdV (BAdV), simian AdV (SAdV), porcine AdV (PAdV), ovine AdV (OAdV), canine AdV (CAdV), avian AdV (AAdV), and murine AdV (MAdV). 8, 9 It has been demonstrated that there were no reductions in humoral and CMI responses against the vaccine immunogen and the resultant protection efficacy of a BAdV type 3 (BAdV-3) vector-based H5N1 influenza vaccine even in the presence of exceptionally high levels of pre-existing HAdV vector immunity. 10 In addition, pre-existing HAdV-neutralizing antibodies in humans did not cross-neutralize BAdV-3, 11 and HAdV-specific CMI responses did not cross-react with BAdV-3. 4 Bio-distribution, pathogenesis, transduction, and persistence studies in animal models and cell lines have suggested that the safety aspects of BAdV vectors are similar to that of HAdV vectors. 12, 13 It has been illustrated that the cell internalization of BAdV-3 is independent of the HAdV type C5 (HAdV-C5) receptors [Coxsackievirus-AdV receptor (CAR) and avb3 or avb5 integrin], 14 but it is indicated that the a(2,3)-linked and a(2,6)-linked sialic acid receptors serve as major receptors for BAdV-3 internalization. 15 It appears that BAdVbased vectors may serve as excellent vaccine vectors for humans without any concerns of pre-existing HAdV vector immunity.
Vaccine formulation features that are important for developing effective pre-pandemic influenza vaccine strategies include the development of balanced humoral and CMI responses that could offer cross-protection, safety, and efficacy with a single dose, dose sparing for vaccine delivery to a large number of individuals, and the capacity to produce a large number of vaccines at short notice. In our previous studies, we have demonstrated that AdV vector-based vaccines could elicit potent humoral and CMI responses in mice conferring crossprotection depending on the immunogen(s) of choice. 16, 17 Because
AdV vectors have been evaluated for their efficacy as gene delivery vehicles in many clinical trials in humans, [18] [19] [20] [21] it is well understood how to produce a clinical grade of purified AdV vector lots in exceptionally large quantities under good laboratory practice (GLP) conditions in certified cell lines in a short time span. 1, [22] [23] [24] In this study, we have compared the immunogenicity and efficacy of BAdV-3 vector (BAd- were evaluated to determine whether the BAdV vector system will serve as a better vaccine vector compared with the HAdV vector. Overall, significantly higher levels of humoral and CMI responses accompanied with higher protection efficacy were observed with the BAd-H5HA vector compared with that of HAd-H5HA. The best protection efficacy with a significantly lower vaccine dose was observed in the mouse group inoculated IN with BAd-H5HA. These results suggest that the BAdV-3-based vector system is a better vaccine delivery vehicle for developing pre-pandemic influenza vaccines. 
RESULTS

HA Expression Levels by HAd-H5HA or BAd-H5HA in Infected Cells
HAd-DE1E3-, HAd-H5HA-, BAd-DE1E3-, or BAd-H5HA-infected BHH3 cells were analyzed to determine the levels of H5 HA expression by immunoblotting using an HA-specific rabbit polyclonal antibody. Roughly equal expression levels of b-actin demonstrate equal loading in each lane (Figure 1 ). Similar densities of HA-specific bands at approximately 72 kDa indicated that HAd-H5HA or BAd-H5HA resulted in a similar level of HA expression ( Figure 1 ).
Induction of Enhanced Humoral Immune Responses with BAd-H5HA Compared with HAd-H5HA
The mouse groups inoculated IN or IM once with 1 Â 10 6 (Figure 2A ), 3 Â 10 6 ( Figure 2B ), 1 Â 10 7 ( Figure 2C ), 3 Â 10 7 ( Figure 2D ), or 1 Â 10 8 ( Figure 2E ) PFUs of HAd-H5HA or BAd-H5HA elicited dose-dependent increases in anti-HA immunoglobulin G (IgG) antibody levels. These levels in the IM-inoculated HAd-H5HA groups were similar to or slightly better than those observed in the similarly inoculated BAd-H5HA groups. In the IN-inoculated BAd-H5HA groups, however, anti-HA IgG antibody levels were significantly higher than those in the similarly or IM-inoculated HAd-H5HA groups, or the IM-inoculated BAd-H5HA groups. The control groups inoculated IN or IM with PBS, HAd-DE1E3, or BAd-DE1E3 did not yield anti-HA IgG antibody levels above background (Figure 2 ).
We have shown previously that animals immunized with AdV vectors expressing HA produce high levels of hemagglutination inhibition (HI) and virus-neutralizing (VN) antibody titers against homologous influenza virus strains. 16, 17, [25] [26] [27] Therefore, here we only tried to determine HI and VN titers against an antigenically distinct influenza virus (VN/1203/RG) that was used for the challenge studies, and we noticed that none of the vaccinated groups developed any detectable HI and VN titers above the empty vector controls (data not shown). These findings were not unexpected because similar results were observed in our previous studies. 17, 28 To determine whether the route of immunization or the vector type will influence the levels of IgG subclasses, the serum samples Because the influenza virus VN/1203/RG, which was used as a challenge virus to evaluate the efficacy of protection, does not cause consistent morbidity or mortality in mice, 16, 17 significant reductions in lung viral titers in vaccinated animals following challenge are a useful measure of the virus clearance and vaccine protective efficacy. The mouse groups were immunized IN or IM once with 1 Â 10 6 (Figure 12A) , 3 Â 10 6 ( Figure 12B ), 1 Â 10 7 ( Figure 12C ), 3 Â 10 7 (Figure 12D) , or 1 Â 10 8 ( Figure 12E ) PFUs of HAd-H5HA or BAd-H5HA, and subsequently challenged with 100 mouse infectious dose 50 (MID 50 ) of VN/1203/RG. For the IN route of inoculation, the lowest vaccine dose of 1 Â 10 6 PFUs of BAd-H5HA conferred complete protection following challenge ( Figure 12A ). The lowest vaccine dose for IN-inoculated HAd-H5HA that yielded complete protection following challenge was 3 Â 10 7 PFUs ( Figure 12E ). For the IM route of inoculation, the lowest vaccine dose for BAd-H5HA that conferred complete protection following challenge was 3 Â 10 7 PFUs (Figure 12D ), but for the IM-inoculated HAd-H5HA animal group, the log lung virus titer with a dose of 1 Â 10 8 PFUs was 1.84 ± 1.14 compared with 4.90 ± 0.42 and 4.6 ± 0.46 log lung virus titers in the empty vector (HAd-DE1E3) or PBS control groups, respectively ( Figure 12E ). Even at a vaccine dose of 3 Â 10 8 PFUs per animal for IM-inoculated HAd-H5HA animal group, the log lung virus titer of 0.84 ± 0.5 was observed following challenge (data not shown).
DISCUSSION
Several studies using AdV vector-based influenza vaccines have been conducted both in animal models 25, 26, 30 and as clinical trials in humans 19, 31 to explore the potential of this vector system. Previously we have shown that AdV vector-based vaccines can provide complete protection against challenge with homologous as well as heterologous (antigenically distinct) influenza virus strains. 25 Moreover, AdV vector vaccines containing multiple HAs from different HA subtypes or expressing nucleoprotein (NP) of H5N1 influenza conferred either complete protection or significant reduction in lung virus titers, respectively, following challenge with pre-pandemic H5, H7, or H9 influenza viruses. 16, 17 The purpose of this study was to determine some of the parameters that are important for a pre-pandemic influenza vaccine including route of immunization, dose sparing, protection from a single dose, and protection against a heterologous influenza virus strain. This study was based on the hypothesis that a combination of HA-specific CMI responses and cross-reactive (although not necessarily cross-neutralizing) humoral immune responses will provide heterologous protection against an antigenically distinct H5N1 influenza virus. In addition, this study also focused on determining the vector type and route of immunization for enhanced immunogenicity conferring efficient protection.
Overall, there were no significant differences in the serum anti-HA IgG, IgG1, IgG2a, and IgG2b or mucosal IgA responses in mouse groups inoculated IM with either BAd-H5HA or HAd-H5HA. However, mice inoculated with BAd-H5HA had higher numbers of IFNg-secreting HA518-specific CD8 T cells in the spleen, lung, and RLNs than the groups inoculated with HAd-H5HA. In contrast, there were no significant differences in the numbers of IFNg-secreting HA518-specific CD8 T cells in the ILNs of the mouse groups inoculated IM with either BAd-H5HA or HAd-H5HA. An intravenous biodistribution study in mice has demonstrated that the BAdV vector genome persists longer and with higher copy numbers in the spleen and lungs than that of the HAdV vector. 12 Similar bio-distribution following the IM route of immunization may be responsible for the higher level of CMI responses with the BAd-H5HA vector. Additional studies will be required to determine the mechanism(s) of these observations. The HK/156 HA expressed in the AdV vectors, and the HA in the challenged virus VN/1203/RG are antigenically different, so it was not surprising that the serum samples from either BAd-H5HA-or HAd-H5HA-inoculated animal groups did not have detectable levels of HI or VN titers against the challenge virus. We purposely opted for antigenically distinct HAs as an immunogen and a challenge virus to test our hypothesis that a combination of CMI responses and nonneutralizing antibodies will provide heterologous protection. The mouse group inoculated IM with 3 Â 10 7 PFUs of BAd-H5HA were completely protected from the challenge with VN/1203/RG, whereas detectable levels (0.84 ± 0.5 log) of lung virus titers were observed in the mouse group IM-inoculated with 3 Â 10 8 PFUs of
HAd-H5HA. These observations suggest that significantly higher levels of CMI responses and non-neutralizing antibodies elicited with BAd-H5HA may be responsible for enhanced protection at a significantly lower dose.
In the mouse groups inoculated IN with BAd-H5HA, levels of serum anti-HA IgG, IgG1, IgG2a, and IgG2b, and levels of mucosal anti-HA IgA were significantly higher than the groups inoculated IM with BAd-H5HA or inoculated IM or IN with HAd-H5HA. Also, the numbers of IFNg-secreting HA518-specific CD8 T cells in the spleen, lung, and RLNs were much higher in BAd-H5HA groups than the HAd-H5HA groups. Additional experiments are required to determine whether the high levels of humoral (systemic and mucosal) and CMI responses are due to better transduction and/or the levels and duration of persistence of the BAdV vector genomes following immunization with BAd-H5HA. Because BAdV-3 utilizes the a(2,3)-linked and a(2,6)-linked sialic acid receptors as the major receptors for virus internalization, 15 whereas HAdV-C5 uses CAR [32] [33] [34] for virus entry in the susceptible cells, we expected that BAd-H5HA will better transduce the respiratory tract following IN inoculation compared with HAd-H5HA. Moreover, the levels and duration of persistence of the BAdV vector genome copy numbers in the lungs were found to be significantly higher than that of the HAdV vector in an intravenous bio-distribution study. 12 There is a possibility that a similar situation may occur following the IN inoculation.
Complete protection from challenge with an antigenically distinct H5N1 influenza virus VN/1203/RG was observed even in the mouse group inoculated IN with 1 Â 10 6 PFUs of BAd-H5HA, whereas a similar level of protection with HAd-H5HA was obtained only with a much higher vector dose of 3 Â 10 7 PFUs. These observations suggest that BAdV vector-based IN vaccine delivery system has considerable promise for dose sparing because an approximately 30-fold lower vaccine dose of BAd-H5HA compared with HAd-H5HA conferred complete protection. Dose sparing not only lowers vaccine costs, but also increases the capacity to produce a large number of doses especially in an event similar to the influenza pandemic. Of course, additional studies will be needed to determine the long-term efficacy of cross-protective humoral and CMI responses induced by BAdV-3-based vectors.
The results described in this manuscript suggest that the BAdV-3-based vector system has many advantages over HAdV systems as a vaccine delivery vehicle for developing pre-pandemic influenza vaccines. Further studies in another animal model of influenza, such as ferrets, will be essential to fully explore the potential of this vaccine delivery system. Additional studies will be required to determine the best combinational antigens or immunogenic domains that could elicit broadly cross-protective immune responses when delivered through the BAdV vector system for developing a universal influenza vaccine for pandemic preparedness and for offering a better vaccine option against seasonal influenza viruses.
MATERIALS AND METHODS
Cell Lines, AdV Vectors, and Influenza Viruses BHH3 (bovine-human hybrid clone 3), 35 BHH2C (bovine-human hybrid clone 2C), 35 293 (human embryonic kidney cells expressing HAdV-C5 E1 proteins), 36 and MDCK (Madin-Darby canine kidney) cell lines were propagated as monolayer cultures in minimum essential medium (MEM) (Life Technologies from Thermo Fisher Scientific, Waltham, MA, USA) containing either 10% reconstituted fetal bovine serum or fetal calf serum (Hyclone from Thermo Fisher Scientific) and gentamycin (50 mg/mL). 25 and HAd-DE1E3 (HAdV-C5 E1 and E3 deleted empty vector) 37 have been described previously. BAd-H5HA and BAd-DE1E3 were grown and titrated in BHH3 cells as described previously, 10 and HAd-H5HA and HAd-DE1E3 were grown in 293 cells and titrated in BHH2C cells as described previously. 17 These vectors were purified by cesium chloride density gradient ultracentrifugation as described previously. 1 Â 10 8 PFUs of BAd-DE1E3 or HAd-DE1E3 served as vector controls. Four weeks post-inoculation, five animals per group were anesthetized with 50 mL ketamine-xylazine solution (90 mg/kg ketamine and 10 mg/kg xylazine in PBS) by intraperitoneal injections, the blood samples were collected via retro-orbital puncture, nasal washes were collected by washing the nasal passage with 0.5 mL of PBS, and the lung washes were prepared after homogenizing one lung from each animal in 1 mL of PBS as described previously. 39 The serum samples, nasal washes, and lung washes were used to evaluate the humoral immune responses. The second lung lobe was processed to collect CD3 + T cells from the lung cells using MagniSort Mouse CD3 Positive Selection Kit following the manufacturer's instructions (Affymetrix eBioscience, San Diego, CA, USA) and used to monitor CMI responses. The spleens, RLNs, and ILNs were also collected to evaluate CMI responses.
The remaining five animals per group were challenged IN with 100 MID 50 of VN/1203/RG. Three days post-challenge, the animals were euthanized under ketamine-xylazine anesthesia as described earlier, and the lungs were collected for determination of the lung virus titers as described previously. 17 
Immunoblotting
HA expression levels in BHH3 cells infected with either HAd-H5HA or BAd-H5HA were determined by immunoblotting following a previously described protocol. 10, 40 An H5 HA-specific polyclonal rabbit antibody was used in immunoblotting.
ELISA ELISA was performed as described earlier. 41, 42 96-well ELISA plates (eBioscience) were coated with purified HA protein (0.5 mg/mL) of HK/156 (MyBioSource, San Diego, CA, USA) and incubated overnight at 4 C. Following blocking with 1% BSA in PBS, diluted serum samples (1:500 dilution for IgG and IgG1 and 1:50 for IgG2a and IgG2b), 1:5 diluted nasal washes, or 1:10 diluted lung washes were added and incubated at room temperature for 2 hr. During the standardization process, various dilutions of each type of sample were tested to establish the best dilution. The horseradish peroxidase-conjugated goat anti-mouse IgG, IgG1, IgG2a, IgG2b, or IgA antibodies (Invitrogen from Thermo Fisher Scientific) at a recommended dilution for each antibody was added and incubated at room temperature for 2 hr. The color development was obtained with a BD OptEIA ELISA TMB substrate (Thermo Fisher Scientific). The reaction was stopped with a 2N sulfuric acid solution, and the optical density readings were obtained at 450 nm using a SpectraMax i3x microplate reader (Molecular Devices, Sunnyvale, CA, USA).
ELISpot Assays
The ELISpot assays were performed as described previously. 25 The splenocytes, lung lymphocytes, RLNs, and ILNs were used for IFNg ELISpot assays after stimulating the cells with HA518 (IYSTVASSL) peptide (H-2K d -restricted CTL epitope for HA). The number of spotforming units (SFUs) was counted using AID ELiSpot reader 8.0 (Autoimmun Diagnostika, Germany).
Statistical Analyses
One-and two-way ANOVAs with Bonferroni post-test were performed to determine statistical significance. The statistical significance was set at p < 0.05. 
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